Danaher Corporation (DAP) Fair Value & Analysis
Healthcare · DE · Market cap €124B
Fair value as of: Jul 15, 2026
From 26 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from €112.34 to €93.15 (−17.1%) since Jun 24, 2026. Share price +10.6% over the past month.
Price vs Fair Value (12 months)
12‑month range €139.81 – €205.73 · fair‑value band €64.67 – €121.32 · the €173.15 price screens above the €93.15 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Danaher Corporation (DAP) currently trades at €173.15, while our model-based Fair Value estimate is €93.15 — implying the stock looks roughly 46.2% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Danaher Corporation generated revenue of €24.8B at a net margin of 14.9%. Revenue grew 3.7% year over year. It earns a return on equity of 7.1%. Net debt stands at €13.8B. Fundamentals as of Jul 15, 2026
Our scenario range runs from €64.67 (bear case) to €121.32 (bull case); at €173.15, the current price sits above that range. The share trades about 17% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside — at -46%, DAP screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Danaher Corporation reported revenue of €24.6B in FY2025 versus €29.5B in FY2021, a compound −4.4%/yr. Reported net income was €3.6B in FY2025, compounding −13.4%/yr from FY2021.
Is DAP fairly valued? → Check now
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | 8,423 MXN | 314.17 MXN | -96% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $61.53 | $15.70 | -74% |
| Agilent Technologies, Inc A | $126.49 | $63.09 | -50% |
| Waters Corporation WAT | $358.25 | $106.31 | -70% |
| Integrated Diagnostics Holdings IDHC | $0.0056 | $0.0100 | +78% |
| IQVIA Holdings IQV | $183.45 | $133.46 | -27% |
| Natera, Inc NTRA | $228.80 | $24.55 | -89% |
| Mettler-Toledo International Inc MTD | $1,133 | $484.94 | -57% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Danaher Corporation (DAP) undervalued?
What is the fair value of DAP?
What is the quality score of DAP?
What is the revenue of Danaher Corporation (DAP)?
What is the net profit margin of DAP?
Does Danaher Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Danaher Corporation analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.